Cancer Immunology Immunotherapy

Founding Editor
G. Mathé

Other Biological Response Modifications

Volume 28 1989

Editors in Chief

R. W. Baldwin **E. Mihich**

Editorial Board

R. Arnon Rehovot
R. Bast Durham, NC
S. Ben-Efraim Tel Aviv
J. Bennett Albany, NY
N. Bloksma Utrecht
H. Blythman Basel
E. C. Borden Madison, WI
V. S. Byers Berkeley, CA
T. Carey Ann Arbor, MI
M. Cheever Seattle, WA
M. Colnaghi Milan
S. Dray Chicago, IL
S. Eccles Sutton, Surrey
I. Fidler Houston, TX
E. Grimm Houston, TX
K. Hellström Seattle, WA
K. Höffken Essen
J. Kieler Copenhagen
H. Kirchner Heidelberg
W. Knapp Vienna
H. Kobayashi Sapporo
M. Mastrangelo Philadelphia, PA
J. McVie Amsterdam
M. Mitchell Los Angeles, CA
M. Moore London
R. J. North Saranac Lake, NY
G. Parmiani Milan
M. Price Nottingham
R. Rees Sheffield
D. Scott Rochester, NY
H.-J. Senn St. Gallen
K. Sikora London
Z. Steplewski Philadelphia, PA
G. Stevenson Southampton
J. Talmadge King of Prussia, PA
E. Tsubura Osaka
A. Uchida Kyoto
F. Vánky Stockholm
E. Vitetta Dallas, TX
B. Vose Cheshire
Y. Yamamura Osaka

Springer International

Cancer Immunology Immunotherapy

Other Biological Response Modifications

This journal was founded in 1976. Founding editor: G. Mathé
Editors: R. W. Baldwin, E. Mihich
Published by Springer International

Copyright

Submission of a manuscript implies: that the work described has not been published before (except in the form of an abstract or as part of a published lecture, review, or thesis); that it is not under consideration for publication elsewhere; that its publication has been approved by all coauthors, if any, as well as by the responsible authorities at the institute where the work has been carried out; that, if and when the manuscript is accepted for publication, the authors agree to automatic transfer of the copyright to the publisher; and that the manuscript will not be published elsewhere in any language without the consent of the copyright holders.

All articles published in this journal are protected by copyright, which covers the exclusive rights to reproduce and distribute the article (e. g., as offprints), as well as all translation rights. No material published in this journal may be reproduced photographically or stored on microfilm, in electronic data bases, video disks, etc., without first obtaining written permission from the publisher.

The use of general descriptive names, trade names, trademarks, etc., in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.

While the advice and information in this journal is believed to be true and accurate at the date of its going to press, neither the authors, the editors, nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

Special regulations for photocopies in the USA: Photocopies may be made for personal or inhouse use beyond the limitations stipulated under Section 107 or 108 of U. S. Copyright Law, provided a fee is paid. This fee is US $ 0.20 per page, or a minimum of US $ 1.00 if an article contains fewer than five pages. All fees should be paid to the Copyright Clearance Center, Inc., 21 Congress Street, Salem, MA 01970, USA, stating the ISSN 0340-7004, the volume, and the first and last page numbers of each article copied. The copyright owner's consent does not include copying for general distribution, promotion, new works, or resale. In these cases, specific written permission must first be obtained from the publisher.

Printed in Germany by E. Kieser GmbH Graphischer Betrieb, D-8902 Neusäß bei Augsburg

© Springer-Verlag Berlin Heidelberg 1989

Contents of volume 28

No. 1 (pp 1– 76) published 24 November 1988
No. 2 (pp 77–156) published 12 January 1989
No. 3 (pp 157–234) published 22 February 1989
No. 4 (pp 235–304) published 3 March 1989

Abe F, Alvord G, Koyama M, Matsuda A, Talmadge JE: Pharmacokinetics of bestatin and oral activity for treatment of experimental metastases 29
Advani SH → Mehta BA
Ahmed K, Turk JL: Effect of anticancer agents neothramycin, aclacinomycin, FK-565 and FK-156 on the release of interleukin-2 and interleukin-1 in vitro 87
Alexander B → Lahat N
Alvord G → Abe F
Aoyama S → Yuh K
Aparicio-Pagés NM, Verspaget HW, Peña SA, Lamers CBHW: Impaired local natural killer cell activity in human colorectal carcinomas 301
Asher AL, Mulé JJ, Rosenberg SA: Recombinant human tumor necrosis factor mediates regression of a murine sarcoma in vivo via Lyt-2$^+$ cells 153
Avner BP → Liao S-K
Baldwin RW → Durrant LG
Berends D, van der Kwast TH, de Both NJ, Mulder PGH: Factors influencing antibody-mediated cytotoxicity during the immunotherapy of Rauscher-virus-induced myeloid leukemic cells 123
Bilik R, Mor C, Hazaz B, Moroz C: Characterization of T-lymphocyte subpopulations infiltrating primary breast cancer 143
Blore J → Brodt P
Böhm M → Lindemann A
Bonta IL → Elliott GR
Borowitz MJ → Hertler AA
Both NJ de → Berends D
Briggs SL → Starling JJ
Bril H → Claessen ME
Brodt P, Blore J, Phillips NC, Munzer JC, Rioux JD: Inhibition of Murine Hepatic tumor growth by liposomes containing a lipophilic muramyl dipeptide 54
Bucana CD → Shimizu H
Bufalino R → Cascinelli N
Cascinelli N, Rümke P, MacKie R, Morabito A, Bufalino R: The significance of conversion of skin reactivity to efficacy of bacillus Calmette-Guérin (BCG) vaccinations given immediately after radical surgery in stage II melanoma patients 282
Claessen ME, Valster H, Bril H, Meyer S, Scheper RJ: Cell-mediated immunity is enhanced by cytostatic drugs continuously released at the site of antigenic stimulation 131
Cobb LM: Intratumour factors influencing the access of antibody to tumour cells 235
Cohen SA → Werner-Wasik M
Deal H, Steele JK, Stammers AT, Singhai R, Levy JG: Preadministration of a T-suppressor factor enhances tumor immunity in DBA/2 mice 193
Debruijne FMJ → Meijden APM van der
Diehl V → Lindemann A
Durrant LG, Robins RA, Marksman RA, Garnett MC, Ogunmuyiwa Y, Baldwin RW: Abrogation of antibody responses in rats to murine monoclonal antibody 791T/36 by treatment with daunomycin-*cis*-aconityl-791T/36 conjugates 37
Ebihara T, Koyama S, Fukao K, Osuga T: Lymphokine-activated suppressor (LAS) cells in patients with gastric carcinoma 218
Elliott GR, Tak C, Bonta IL: Prostaglandin E_2 enhances, and leukotriene C_4 inhibits, interleukin-1 inhibition of WEHI-3B cell growth 74
Fady C → Reisser D
Formenti SC, Mitchell MS, Taylor CR, Lipkin M, Jernstrom PH, Kan-Mitchell J: Reactivity of a human monoclonal antibody against carcinomas and other lesions of the colon 296
Fossati G → Radrizzani M
Frankel AE → Hertler AA
Franks CR → Lindemann A
Frost P → Itaya T
Fukao K → Ebihara T
Gambacorti-Passerini C → Radrizzani M
Gamm H → Lindemann A
Garnett MC → Durrant LG
Guillou PJ, Sedman PC, Ramsden CW: Inhibition of lymphokine-activated killer cell generation by cultured tumor cell lines in vitro 43
Hagenaars AM → Meijden APM van der
Hara T → Umemoto N
Harthoorn-Lasthuizen EJ → Meijden APM van der
Hashimoto S, Nagaoka M, Hayashi K, Yokokura T, Mutai M: Role of culture supernatant of cytotoxic/cytostatic macrophages in activation of murine resident peritoneal macrophages 253
Hayashi K → Hashimoto S
Hayashi S → Hosoe S
Hayungs J → Lindemann A
Hazaz B → Bilik R
Herrmann F → Lindemann A
Hertler AA, Schlossman DM, Borowitz MJ, Poplack DG, Frankel AE: An immunotoxin for the treatment of T-acute lymphoblastic leukemic meningitis: studies in rhesus monkeys 59
Hilgard P → Reissmann T
Hines DL: Failure of specific adoptive immunotherapy owing to survival and outgrowth of variant cells 241
Hinson NH → Starling JJ
Höffken K → Lindemann A
Hoegen R von → Schild H
Hoogstraaten IMW van → Meijden APM van der
Hosoe S, Ogura T, Hayashi S, Komuta K, Ikeda T, Shirasaka T, Kawase I, Masuno T, Kishimoto S: Induction of tumoricidal macrophages from bone marrow cells of normal mice or mice bearing a colony-stimulating-factor-producing tumor 116
Hunt B → Itaya T
Husseini S → Liao S-K
Ichihara I → Yuh K
Ikeda T → Hosoe S
Inamura N, Sone S, Okubo A, Kunishige F, Nakanishi M, Ogura T: Tumor cytotoxicity of human monocyte membrane-bound interleukin-1α induced by synergistic actions of interferon-γ and synthetic acyltripeptide, FK--565 164
Itaya T, Hunt B, Frost P: Retention of immunogenicity after X-irradiation of mouse colon tumor cells expressing the transfected influenza virus hemagglutinin gene 248
Janson CH, Tehrani MJ, Mellstedt H, Wigzell H: Anti-idiotopic monoclonal antibody to a T-cell chronic lymphatic leukemia. Characterization of the antibody, in vitro effector functions and results of therapy 225
Jeannin JF → Reisser D
Jernstrom PH → Formenti SC
Jong WH de → Meijden APM van der
Kan-Mitchell J → Formenti SC
Kan N, Okino T, Nakanishi M, Satoh K, Ohgaki K, Tobe T: In vivo and in vitro synergistic antitumor effect of interleukin-2-cultured tumor-bearer spleen cells and immune fresh spleen cells 260
Kato Y → Umemoto N
Kawase I → Hosoe S
Kellokumpu-Lehtinen P, Nordmann E, Toivanen A: Combined interferon and vinblastine treatment of advanced melanoma: evaluation of the treatment results and the effects of the treatment on immunological functions 213
Kerckhaert JA → Meijden APM van der
Kikuchi M → Yuh K
Kimbro B → Liao S-K
Kishimoto S → Hosoe S
Klein E → Vánky F
Kleinerman ES → Shimizu H
Kloke O → Lindemann A
Knowles RD → Shimizu H
Kolitz JE → Lindemann A
Komuta K → Hosoe S
Koyama M → Abe F
Koyama S → Ebihara T
Kunishige F → Inamura N
Kuriyama H → Watanabe N
Kwast TH van der → Berends D
Lagadec P → Reisser D
Laguzza BC → Starling JJ
Lahat N, Alexander B, Levin DR, Moskovitz B: The relationship between clinical stage, natural killer activity and related immunological parameters in adenocarcinoma of the prostate 208

Lamers CBHW → Aparicio-Pagés NM
Lenz B → Talmadge JE
Levin DR → Lahat N
Levy JG → Deal H
Lewis JL Jr → Mattes MJ
Liao S-K, Meranda C, Avner BP, Romano T, Husseini S, Kimbro B, Oldham RK: Immunohistochemical phenotyping of human solid tumors with monoclonal antibodies in devising biotherapeutic strategies 77
Lindemann A, Höffken K, Schmidt RE, Diehl V, Kloke O, Gamm H, Hayungs J, Oster W, Böhm M, Kolitz JE, Franks CR, Herrmann F, Mertelsmann RH: A phase-II study of low-dose cyclophosphamide and recombinant human interleukin-2 in metastatic renal cell carcinoma and malignant melanoma 275
Lipkin M → Formenti SC
Lloyd KO → Mattes MJ
Long C → Talmadge JE
Maciak RS → Starling JJ
MacKie R → Cascinelli N
Maeda M → Watanabe N
Marksman RA → Durrant LG
Masuno T → Hosoe S
Matsuda A → Abe F
Mattes MJ, Lloyd KO, Lewis JL, Jr: Binding parameters of monoclonal antibodies reacting with ovarian carcinoma ascites cells 199
Mehta BA, Satam MN, Advani SH, Nadkarni JJ: In vitro modulation of natural killer cell activity in non-Hodgkin's lymphoma patients after therapy 148
Meijden APM van der, Steerenberg PA, Hoogstraaten IMW van, Kerckhaert JA, Schreinemachers LMH, Harthoorn-Lasthuizen EJ, Hagenaars AM, de Jong WH, Debruijne FMJ, Ruitenberg EJ: Immune reactions in patients with superficial bladder cancer after intradermal and intravesical treatment with bacillus Calmette-Guérin 287
Mellstedt H → Janson CH
Meranda C → Liao S-K
Mertelsmann RH → Lindemann A
Meyer S → Claessen ME
Mitchell MS → Formenti SC
Morabito A → Cascinelli N
Mor C → Bilik R
Moroz C → Bilik R
Moskovitz B → Lahat N
Muenchhausen W von → Werner-Wasik M
Mulder PGH → Berends D
Mulé JJ → Asher AL
Munzer JC → Brodt P
Mutai M → Hashimoto S
Nadkarni JJ → Mehta BA
Nagaoka M → Hashimoto S
Nakanishi M → Inamura N
Nakanishi M → Kan N
Neda H → Watanabe N
Nichols CL → Starling JJ
Niitsu Y → Watanabe N
Nolan JP → Werner-Wasik M
Nordmann E → Kellokumpu-Lehtinen P
Ogunmuyiwa Y → Durrant LG
Ogura T → Hosoe S
Ogura T → Inamura N
Ohgaki K → Kan N
Ohtsuka Y → Watanabe N
Okino T → Kan N
Okubo A → Inamura N
Okumura M → Yuh K
Oldham RK → Liao S-K
Olsson NO → Reisser D
Oster W → Lindemann A
Osuga T → Ebihara T
Parmiani G → Radrizzani M
Parmiani G → Rodolfo M
Pelletier H → Reisser D
Peña SA → Aparicio-Pagés NM
Phillips H → Talmadge JE
Phillips NC → Brodt P
Pohl J → Reissmann T
Poplack DG → Hertler AA
Puri RK, Rosenberg SA: Combined effects of interferon α and interleukin 2 on the induction of a vascular leak syndrome in mice 267
Radrizzani M, Gambacorti-Passerini C, Parmiani G, Fossati G: Lysis by interleukin 2-stimulated tumor-infiltrating lymphocytes of autologous and allogeneic tumor target cells 67
Ramsden CW → Guillou PJ
Reisser D, Fady C, Pelletier H, Lagadec P, Jeannin JF, Olsson NO: Comparative effect of rat and fetal calf serum on measurement of the natural tumoricidal activity of rat lymphocytes, macrophages and polymorphonuclear cells 34
Reissmann T, Voegeli R, Pohl J, Hilgard P: Augmentation of host antitumor immunity by low doses of cyclophosphamide and mafosfamide in two animal tumor models 179
Rioux JD → Brodt P
Robins RA → Durrant LG
Rodolfo M, Salvi C, Parmiani G: Influence of the donors' clinical status on in vitro and in vivo tumor-cytotoxic activation of interleukin-2-exposed lymphocytes and their circulation in different organs 136
Romano T → Liao S-K
Rosenberg SA → Asher AL
Rosenberg SA → Puri RK
Rotstein S → Vánky F
Ruitenberg EJ → Meijden APM van der
Rümke P → Cascinelli N
Ryoyama C, Ryoyama K: Effects of injection routes of growing tumors PSK or OK-432 on antiproliferative activity of mouse serum 101
Ryoyama K → Ryoyama C
Salvi C → Rodolfo M
Satam MN → Mehta BA
Satoh K → Kan N
Scheper RJ → Claessen ME
Schild H, von Hoegen R, Schirrmacher V: Modification of tumor cells by a low dose of Newcastle disease virus. II. Augmented tumor-specific T cell response as a result of $CD4^+$ and $CD8^+$ immune T Cell cooperation 22
Schirrmacher V → Schild H
Schlossman DM → Hertler AA
Schmidt RE → Lindemann A
Schneider M → Talmadge JE
Schreinemachers LMH → Meijden APM van der
Sedman PC → Guillou PJ
Shimizu H, Wyatt D, Knowles RD, Bucana CD, Stanbridge EJ, Kleinerman ES: Human monocytes selectively bind to cells expressing the tumorigenic phenotype 185
Shimizu M → Yuh K
Shirasaka T → Hosoe S
Singhai R → Deal H
Sone H → Watanabe N
Sone S → Inamura N
Stammers AT → Deal H
Stanbridge EJ → Shimizu H
Starling JJ, Maciak RS, Hinson NH, Nichols CL, Briggs SL, Laguzza BC: In vivo efficacy of monoclonal antibody – drug conjugates of three different subisotypes which bind the human tumor – associated antigen defined by the KS1/4 monoclonal antibody 171
Steele JK → Deal H
Steerenberg PA → Meijden APM van der
Stuber G → Vánky F
Tak C → Elliott GR
Talmadge JE → Abe F
Talmadge JE, Lenz B, Schneider M, Phillips H, Long C: Immunomodulatory and therapeutic properties of FK-565 in mice 93
Taylor CR → Formenti SC
Tehrani MJ → Janson CH
Tobe T → Kan N
Toivanen A → Kellokumpu-Lehtinen P
Turk JL → Ahmed K
Umemoto N, Kato Y, Hara T: Cytotoxicities of two disulfide-bond-linked conjugates of methotrexate with monoclonal anti-MM46 antibody 9
Valster H → Claessen ME
Vánky F, Stuber G, Rotstein S, Klein E: Auto-tumor recognition following in vitro induction of MHC antigen expression on solid human tumors: stimulation of lymphocytes and generation of cytotoxicity against the original MHC-antigen-negative tumor cells 17
Verspaget HW → Aparicio-Pagés NM
Voegeli R → Reissmann T
Watanabe H → Yuh K
Watanabe N, Neda H, Ohtsuka Y, Sone H, Yamauchi N, Maeda M, Kuriyama H, Niitsu Y: Signalling pathway of tumor necrosis factor in normal and tumor cells 157
Werner-Wasik M, von Muenchhausen W, Nolan JP, Cohen SA: Endogeneous interferon α/β produced by murine Kupffer cells augments liver-associated natural killing activity 107
Wigzell H → Janson CH
Wyatt D → Shimizu H
Yamauchi N → Watanabe N
Yokokura T → Hashimoto S
Yuh K, Shimizu M, Aoyama S, Ichihara I, Watanabe H, Okumura M, Kikuchi M: Immunological analysis and characterization of lymphocyte subsets in specimens of human hepatocellular carcinomas and metastatic liver cancers 1